FCRL2 and leukemia: These included the associations of TNFRSF13B and SLAMF7 with risk of multiple myeloma [HR (95%CI): 2.09 (1.96–2.24) and 3.07 (2.73–3.46), respectively], PDCD1 and TNFRSF9 with risk of NHL [1.99 (1.87–2.11) and 1.98 (1.85–2.11), respectively], and FCER2 and FCRL2 with risk of leukaemia [2.12 (1.98–2.29) and 2.10 (1.95–2.26), respectively].